Jump to content
  • Sign Up
0
Scott Adams

BioLineRx BL-7010 may reduce gluten toxicity in patients with celiac disease - News-Medical.net

Rate this topic

Recommended Posts

BioLineRx BL-7010 may reduce gluten toxicity in patients with celiac disease

News-Medical.net

BioLineRx (NASDAQ: BLRX)(TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect ...

BioLineRx Announces Publication of Pre-Clinical Results Demonstrating Efficacy ... Business Wire (press release)

From Earlier: BioLineRx Announces Publication of Pre-Clinical Results ... Benzinga

all 16 news articles »

View the full article

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
0

×